Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 13-04-2018

Legal Publication Date:- 03-05-2018

Journal Code (1805032)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

09-04-2018		
228/2018	COMSATS Institute of Information Technology (CIIT), Lahore - Pakistan	"One-step Dual Heather Based Flow Synthesis Setup for Synthesis of Inorganic Particles in Near Ambient Conditions"
229/2018	YKK CORPORATION Japan (Priority 14-04-2017 JP)	"METHOD AND APPARATUS FOR ELECTROPLATING"
230/2018	MUHAMMAD AQIB MUHAMMAD JAVED Lahore – Pakistan	"Aab-e-Hayyat Purifier"
231/2018	AstraZeneca AB Sweden (Priority 27-04-2017 US)	"C_5-anilinoquinazoline Compounds and Their Use in Treating Cancer"
10-04-2018		
232/2018	Afzaal Mustafa Islamabad	"Sun Shade"
233/2018	Takeda Pharmaceutical Company Limited Japan (Priority 11-03-2013 US) **Divisional**	"PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF"

234/2018	Muhammad Usman Akram Sajid Gul Khawaja **NUST** Peshawar – Pakistan	"Apparatus and System for Retinal Screening using Smatphone"
235/2018	LAHORE UNIVERSITY OF MANAGEMENT SCIENCES (LUMPS) Lahore – Pakistan	"RF GSM based Clock Synchronization for Internet of Things (IoT)
236/2018	Evonik Degussa GmbH Germany (Priority 10-11-2017 EP)	"Process for extracting fatty acids from triglyceride oils"
11-04-2018		
237/2018	Muhammad Awais Islamabad – Pakistan Agha Hassan Feroz Rawalpindi – Pakistan	"TEC based temperature transition embedded into a household drinking glass"
238/2018	COTY INC. USA (Priority 12-04-2017 EP)	"METHOD FOR TREATING HAIR, KIT, AND USE OF THE KIT"
239/2018	Novartis AG Switzerland (Priority 12-04-2017 US)	"USE OF LIK066 IN HEART FAILURE PATIENTS"
12-04-2018		
240/2018	SAEED UR REHMAN Gujrat – Pakistan	"MEDICAL TREATMENT FOR CANCER"
241/2018	ELI LILLY AND COMPANY USA (Priority 11-09-2014 US)	"PROCESS FOR THE PREPARATION OF COMPOUND AND PHARMACEUTICAL DOSAGE

	Divisional	FORM THEREOF"
13-04-2018		
242/2018	Meiji Co., Ltd., Japan (Priority 14-04-2017 JP)	"COMPOSITION FOR ACTIVATING TOLL-LIKE RECEPTOR 2"
243/2018	BAYER AKTIENGESELLSCHAFT Germany (Priority 21-04-2017 EP)	"MESOIONIC IMIDAZOPYRIDINES AS INSECTICIDES"
244/2018	ROBOART (PVT.) LIMITED Lahore - Pakistan	"CAR CHABI, MOBOKEY (INTEGRATING CURRENT CAR CHABI APP WITH TRACKING APP)"

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as certained on application to the office.

1304/2006	Novartis AG Switzerland	"2-Amino-7,8-Dihydro-6H-Pyrido[4,3-D]Pyrimidin-5-one" C07D471/04. **142740** Disclosed are 2-amino-7, 8-dihydro-6H-pyrido [4,3 -d]pyrimidin-5 -one compound, that include one or more of the 2-amino-7, 8-dihydro-6H-pyrido [4,3 -d]pyrimidin-5 -one compound, either alone or in combination with at least one additional therapeutic agent. 

933/2009	Sanofi-Aventis Deutschland GmbH Germany	"COMBINATION OF AN INSULIN AND A GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONIST" A61K38/28, A61K38/26 & A61P5/50. **142741** The invention relates to a medicament comprising at least one insulin and at least one glucagon-like peptide 1 (GLP-1) receptor agonist, the medicament being formulated and/or compounded in such a way that it comprises the insulin and the GLP-1 agonist each in a predetermined amount and can be administered in a dose adapted to the individual requirement of a patient.
1093/2009	EURO-CELTIQUE S.A., Luxembourg	"Process for the preparation of (S)-Dihydroetorphine" C07D489/12, A61K31/4353 & A61P20/100. **142742** The present invention provides a process for the preparation of a compound of formula (VI),  (VI) wherein R^1 and R^2 are independently C_{1-8} straight-chain alkyl and * represents a stereocentre.
1010/2010	ELI LILLY AND COMPANY U.S.A	"4-SUBSTITUTED BICYCLO[3.1.0] HEXANE COMPOUND"

		A61K31/4196, A61P25/00, C07D209/26 & C07D249/10. **142743** The present invention provides compounds of the formula  wherein R^1 is hydrogen, R^2 is hydrogen, and R^3 is hydrogen; R^1 is hydrogen, R^2 is (2S)-2-aminopropanoyl, and R^3 is hydrogen; R^1 is hydrogen, R^2 is (2S)-2-amino-4-methylsulfanyl-butanoyl, and R^3 is hydrogen; R^1 is hydrogen, R^2 is (2S)-2-amino-4-methyl-pentanoyl, and R^3 is hydrogen; R^1 is hydrogen, R^2 is 2-aminoacetyl, and R^3 is hydrogen; R^1 is benzyl, R^2 is hydrogen, and R^3 is benzyl; or R^1 is (2-fluorophenyl)methyl, R^2 is hydrogen, and R^3 is (2-fluorophenyl)methyl; useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
350/2011	SANOFI-AVENTIS France	"AN AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE" **142744** The present invention relates to an aqueous pharmaceutical formulation comprising 300 U/mL [equimolar to 300 IU human insulin] of insulin glargine and an analogue of exendin-4 selected from a group comprising lixisentatide, exenatide and liraglutide for use in the treatment of Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus.
369/2011	Regeneron Pharmaceuticals, Inc.	"AN ISOLATED ANTIBODY TO HUMAN GROWTH AND DIFFERENTIATION FACTOR-8 (GDF8)"

	U.S.A.	C07K16/22. **142745** An isolated human or humanized antibody or a fragment thereof which specifically binds to Growth and Differentiation Factor-8 (GDF8) and blocks GDF8 activity, is provided. The antibody or antibody fragment is useful in a therapeutic method for treating a condition or disorder which is ameliorated or improved by inhibition of GDF8, such as loss of muscle tissue, associated with muscle dystrophy, muscle atrophy, muscle wasting syndrome, sarcopenia or cachexia; impaired metabolism or type II diabetes to improve glucose homeostasis, decrease fat mass, increase insulin sensitivity, improve kidney function and/or decrease fat accumulation; or a condition characterized by bone loss, for example, associated with osteoporosis, osteopenia, osteoarthritis and/or bone fractures.
611/2011	Corn Products Development, Inc. USA.	"A Method for modifying a carbohydrate using hydroxyl radicals" A23L1/0522 & A23L1/09. **142746** Disclosed herein are methods for modifying carbohydrates using hydroxyl radicals. The hydroxyl radicals may be formed by the photolysis of peroxide in aqueous solution using UV light. Also disclosed are compositions and products comprising carbohydrates modified by the process. The method for modifying a carbohydrate comprises forming a carbohydrate slurry with a solvent and reacting the carbohydrate with hydroxyl radicals, wherein the hydroxyl radicals are continuously generated by the photolysis of peroxide in aqueous solution using UV light, the ratio of UV light to peroxide is in the range of about 20-500 watts/g, the ratio of peroxide weight relative to carbohydrate weight is in the range of about 0.1 to 2.5% wt/wt, and the pH of the slurry is maintained between 7 to 11.

851/2011	ELI LILLY AND COMPANY U.S.A.	"PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATES OF THE SALT FOR 4-SUBSTITUTED BICYCLO[3.1.0] HEXANE COMPOUND" C07D209/26 & A61K31/96. **142647** The present invention provides pharmaceutically acceptable salts or solvates of the salts for the compounds of the formula  wherein R^1 is hydrogen, R^2 is hydrogen, and R^3 is hydrogen; R^1 is hydrogen, R^2 is (2S)-2-aminopropanoyl, and R^3 is hydrogen; R^1 is hydrogen, R^2 is (2S)-2-amino-4-methylsulfanyl-butanoyl, and R^3 is hydrogen; R^1 is hydrogen, R^2 is (2S)-2-amino-4-methyl-pentanoyl, and R^3 is hydrogen; R^1 is hydrogen, R^2 is 2-aminoacetyl, and R^3 is hydrogen; R^1 is benzyl, R^2 is hydrogen, and R^3 is benzyl; or R^1 is (2 -fluorophenyl)methyl, R^2 is hydrogen, and R^3 is (2-fluorophenyl)methyl; useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
297/2012	Monsanto Technology LLC U.S.A.	"PLANT REGULATORY ELEMENTS AND USES THEREOF" C12N15/82 & A01H5/00. **142748**

		The invention provides DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. Transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of their use.
556/ 2012	INVISTA Technologies S.a r.l. Switzerland.	"FLAME RESISTANT YARN AND FABRIC INCLUDING PARTIALLY AROMATIC POLYAMIDE FIBER AND OTHER FLAME RESISTANT FIBER" D02G3/04, D03D15/12 & D03D15/00. **142749** The present invention provide an article exhibiting flame resistant or flame retardant property comprising fiber and yarn which are made with partially aromatic polyamides and a fiber having vapor phase action such as an flame resistant cellulosic fiber. The fabric made from such fiber and yarn demonstrates superior flame retardancy over traditional flame retardant nylon 6, 6 fabrics. The present invention further provides, the fiber and yarn when blended with other flame retardant fiber then it does not demonstrate the dangerous "scaffolding effect", whereas, this effect is common with flame retardant nylon 6, 6 blended fabrics.
774/ 2012	CJ CHEILJEDANG CORPORATION Republic of Korea.	"A BACTERIOPHAGE HAVING A SPECIFIC BACTERICIDAL ACTIVITY AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI" **142750** The present invention relates to a novel bacteriophage having an E.coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E.coli comprising the

		bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activityagainst pathogenic E.coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E.coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.
06/2013	Alpinestars Research Srl. Italy.	"HELMET WITH AN ADJUSTABLE DEVICE" A42B3/12. **142751** The present invention relates to a helmet 10 which comprises an impact absorbing liner 30 and a comfort liner 40. The comfort liner 40 in turn comprises at least one adjustable device 50 which during the normal use of the helmet 10 is positioned on the top of the head of the user. According to the invention, the adjustable device 50 is suitable for being fastened to the impact absorbing liner 30 of the helmet 10 by means of coupling means 80 provided at the ends 64 of the adjustable device 50. The coupling means 80 are suitable for being removably engaged inside anchor means 90 provided on the impact absorbing liner 30 of the helmet 10. Each anchor means 90 has a plurality of anchor points 94A, 94B, 94C. By changing the anchor point 94A, 94B, 94C where the coupling means 80 of the adjustable device 50 are engaged, the user is allowed to adjust the conformation and slope of the adjustable device 50 of the helmet 10 according to needs.

		
90/ 2013	Saurer Components GmbH Germany	"DRAFTING ARRANGEMENT FOR DRAWING A ROVING YARN" D01H1/02, D01H1/14 & D01H13/02. **142752** The invention relates to a drafting arrangement for drawing a roving yarn with drafting fields formed by feed, centre and withdrawal roller pairs, and a connected compression zone, wherein top delivery rollers are connected to the top withdrawal rollers by means of a cage element and the cage element is loaded by a pressure element in the direction of the bottom delivery rollers. According to the invention it is provided that the pressure element (15) is a spring element, which is configured to be length-variable in its longitudinal direction and is supported in an articulated manner, in each case, on bearing points at its two ends (32, 33). 

105/ 2013	Regeneron Pharmaceuticals, Inc. U.S.A.	"ANTI-BIG-ENDOTHELIN-1 (BIG-ET-1) ANTIBODY" C07K16/26. **142753** The present invention provides antibody that bind big-endothelin-1 ("big-ET-1"). According to certain embodiments of the invention, the antibody specifically binds human big-ET-1 but does not bind human small-ET-1 (i.e., the active form of endothelin-1 that results from proteolytic cleavage of big-ET-1 by endothelin-converting enzyme-1 (ECE-1]). According to certain embodiments of the invention, the anti-big-ET-1 antibody is capable of blocking cleavage of big-¬ET-1 by ECE-1. The antibody of the invention is useful for the treatment of hypertension disorders and cancers.
24/2014	Merck Sharp & Dohme Corp., U.S.A.	"A heterocycle-substituted tetracyclic compound and pharmaceutical composition comprising it for HCV treatment" C07D491/052, A61K31/675 & A61P31/14. **142754** The present invention relates to novel Heterocycle-Substituted Tetracyclic compound of having the structure:  Wherein substituents are as defined herein. The present invention also relates to compositions comprising said Heterocycle-Substituted

		Tetracyclic compound, for use in treating or preventing HCV infection in a patient.
123/ 2014	ELI LILLY AND COMPANY U.S.A.	"N-[3-[(4aR,7aS)-2-Amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo [3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-2-carboxamides" C07D513/04, A61K31/547 & A61P25/28. **142755** The present invention provides a compound of Formula I:  Formula I wherein R is H or F; and A is:  The present invention further provides a pharmaceutical composition comprising above said compound along with one or more pharmaceutically acceptable carriers, diluents, or excipients, which is useful in treating and preventing Alzheimer's disease.
422/ 2014	Rhizen Pharmaceuticals SA, Switzerland	" 2-(1-(9H-purin-6-ylamino) propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and its isomer as dual selective PI3 Delta and Gamma kinase inhibitor" C07D473/04, A61K31/52 & A61P35/00. **142756**

		The present invention relates to 2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and its isomer as dual delta (δ) and gamma (γ) PI3K protein kinase modulator, method of preparing them, pharmaceutical composition containing them and, prevention and/or amelioration of PI3K kinase mediated diseases or disorders with them.
450/2014	SANTONI S.P.A. Italy.	"Device for Feeding Thread to Needles of a Knitting Machine" D04B15/60. **142757** A device (1) for feeding thread to the needles (N) of a knitting machine, the device comprising a body (2) destined to be associated to a needle-bearing organ of the knitting machine, and provided with at least a housing seating (3) configured such as to movably house the thread guide means (4) in the body. The device is provided with thread guide means (4), movably housed in the housing seating (3) and comprising a first lever (5), a thread guide (6) and a second lever (10). The first lever is rotatably mounted to the body (2) such as to be able to rotate about a first rotation axis (X); the thread guide is rotatably mounted to the first lever (5) so as to be able to rotate, with respect to the first lever, about a second rotation axis (Y). The thread guide extends longitudinally between a rear end (7) and a front end (8); the front end (8) extends and emerges from the seating (3) in the direction of the needle-bearing organ, and defines at least a passage (61) for a thread to be dispensed to the needles (N) of the needle-bearing organ; the thread guide is further provided with a guide portion (9). The second lever (10) is rotatably mounted to the body (2) so as to be rotatable about a third rotation axis (Z) and extends between an activating end (11) and a guide end (12), to which the guide portion (9) of the thread guide is maintained slidably in contact. The thread guide means further comprise activating means which controlledly move the first

		(5) and the second lever (10) so as to position the thread guide (6) in a plurality of operating positions with respect to the needle-bearing organ of the knitting machine. 
484/2014	1)Salma Bilal 2)Imran Khan 3) Anwar-ul-Haq Ali Shah Pakistan	"Electrochemical Synthesis of Soluble Polyaniline" C08J5/18. **142758** A strategy including combining a monomer, an acid and a surfactant, subjecting it to optimized potential cycling in a three electrode cell and recovering pure and doped polyaniline from it on the surface of electrode in the form of electroactive film or scratching it in the form of powder soluble in water as well as organic solvents. Where in the monomer is aniline and the surfactant is either dodecylbenzene sulfonic acid (DBSA) or ammonium lauryl sulphate, the acidic medium comprises of sulfuric acid. The strategy has the potential to be used in technologies where direct synthesis of the polyaniline film on the surface of electrode or rapid collection of the soluble polyaniline, without involving too much chemicals, is desired.

		 *Figure. Solutions of the electrochemically synthesized polyaniline in (1) dimethylsulfoxide (2) ethanol (3) chloroform (4) toluene (5) acetone (6) propanol (7) butanol (8) water.*
659/2014	F. Hoffmann-La Roche AG Switzerland	"Substituted phenyl-ethynyl Compound" C07D405/114, A61P25/24 & A61K31/517. **142759** The present invention relates to a compound of formula I  I wherein Y is N or C-R^1; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with different N- positions, imidazolyl, pyrazinyl, pyrimidinyl, thiophenyl, thiazolyl, pyrazoiyi or thiadiazolyl, which are optionally substituted by 1,2 or 3 substituents, selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or NRR'; R and R' are independently from each other hydrogen or lower alkyl, or may form together with the N atom to which they are attached a five or six membered saturated heterocyclic group

		which may contain an additional oxygen, NH, or N-lower alkyl group; R^1 is hydrogen, halogen or lower alkyl substituted by halogen; $R^{1'}$ is hydrogen, halogen or lower alkyl substituted by halogen; R^2 is hydrogen, lower alkyl, lower alkoxyalkyl, cycloalkyl or heterocycloalkyl; or R^2 may form together with the closest carbon atom in group G a group  for A being $-CH_2-$, $-CH_2CH_2$, or $-C(CH_3)_2-$, R^3 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; It has been surprisingly been found that the compound of general formula I is positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4), useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
768/ 2014	FMC Corporation U.S.A.	"THE METHOD OF TREATMENT OF SEED AND THE COATED SEED THEREOF" A01C1/06. **142760** The present invention relates to the method of seed treatment comprising (a) applying a coating of an alginate, optionally containing one or more crop protection agents selected from the group consisting of insecticides, nematocides and fungicides, and /or one more nutrients, to the seed; and (b) crosslinking the alginate with the divalent metal ion, applied to the seed. The invention further relates to the coated seeds including a plant

		seed and a controlled release coating comprising crosslinked alginate with divalent metal ion ,and a crop protection agent and / or one or more nutrients, and combinations thereof.
907/2014	1) Eisai R & D Management Co., Ltd. Japan. 2) PRISM Pharma Co., Ltd. Japan.	" (6S-9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}-methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino [2,1-c][1,2,4]triazine-1-carboxamide compound" **142761** The present invention provides a compound (6S,9aS)-N-benzyl-8-((6-(3-(4-ethylpiperazin-1 -yl)azetidin-1 -yl)pyridin-2-yl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)-4,7-dioxo-2-(prop-¬2-en-1 -yl)-octahydro- 1H-pyrazino[2, 1-c] [1 ,2,4]triazine- 1 -carboxamide. The present invention further provides a pharmaceutical composition comprising above said compound. The compound of present invention has a Wnt Pathway modulating activity.
118/2015	SINTETICA S.A. Switzerland.	" Process for producing a stable low concentration, injectable solution of noradrenaline" A61K9/00, A61K47/02 & A61K31/135. **142762** In a first aspect, the present invention relates to process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents.

479/2015	Honda Motor Co., Ltd. Japan	"VEHICLE BODY REAR PORTION STRUCTURE COMPRISING LEFT AND RIGHT SIDE FRAMES" B62D25/20. **142763** The present invention provides a vehicle body (20) rear portion structure comprising left and right rear side frames (21, 22) positioned in the left and right ends of the rear portion of the vehicle body and extending longitudinally, a rear end cross member (25) spanning between and joined to the rear ends of the left and right rear side frames (21, 22), and a cross member (24) spanning between and joined to the left and right rear side frames (21, 22) in front of the rear end cross member (25). A first longitudinal member (26) and left and right second longitudinal members (27, 28) span between and join the cross member (24) and the rear end cross member (25). The first longitudinal member (26) is positioned in the lateral middle. The left and right second longitudinal members (27, 28) are positioned between the first longitudinal member (26) and the left and right rear side frames (21, 22) respectively, and define an arch shape in which the longitudinally central regions protrude upward.
812/2015	Novartis AG Switzerland.	" ISOXAZOLE HYDROXAMIC ACID COMPOUND AS LpxC INHIBITOR" C07D413/06, C07D413/12 & A61K31/42. **142764** The present invention relates to a compound of Formula (I):  (I) wherein:

		X is —NH-, and R^1 is —CH(OH)-Y; or X is —CH_2-, and R^1 is —CH(OH)-Y or —SO_2R^2 where R^2 is C_1-C_3 alkyl; R^3 is H or halo; Y is selected from a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S as ring members, phenyl, and C1-3 alkyl, and each Y is optionally substituted with one to three R^4; each R^4 is independently selected from halo, C_{1-3} alkyl, and C_{3-6} cycloalkyl, wherein the C_{1-3} alkyl and C_{3-6} cycloalkyl are each optionally substituted with up to three groups selected from halo, CN and -OH; L is —C≡C- or —CR^5=CR^5-; R^5 is independently selected at each occurrence from H, halo and methyl; and Z is selected from C_{1-6} alkyl, C_3-C_6 cycloalkyl, pyridinyl, and phenyl, each of which is optionally substituted with up to three groups selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} haloalkoxy, CN, and C_{1-4} alkyl that is optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C_{1-3} alkoxy; or, when L is —CR^5=CR^5- , Z taken together with one of the R^5 groups and any atoms connecting Z with the R^5 group can form a 3-7 membered cycloalkyl or cycloalkenyl group that is optionally substituted with up to three groups selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} haloalkoxy, CN, and C_{1-4} alkyl that is optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C_{1-3} alkoxy. The invention further provides a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier which therapeutically effective to treat bacterial infections caused by Gram-negative bacteria.
836/2015	Novartis AG. Switzerland.	"PHARMACEUTICAL PRODUCT AND STABLE LIQUID COMPOSITION OF SECUKINUMAB" A61K39/395 & C07K16/24. **142765**

		The present invention is directed to a pharmaceutical product comprising: a. a container having a headspace, wherein the oxygen content in the headspace is less than about 12%, and b. a liquid pharmaceutical composition having a pH of about 5.2 to about 6.2 disposed within said container, said composition comprising: i. about 20 mg/ml to about 175 mg/ml secukinumab; and ii. about 2.5 to about 20 mM L-methionine, wherein the liquid pharmaceutical composition is not reconstituted from a lyophilisate. The pharmaceutical product and liquid composition of the present invention is therapeutically effective for the treatment of various IL- 17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).
29/2016	LONATI S.P.A., Italy.	"CIRCULAR HOSIERY KNITTING MACHINE,PARTICULARLY OF THE DOUBLE CYLINDER TYPE,WITH YARN FINGER FOR PLATED KNITTING" D04B15/58. **142766** A circular hosiery knitting machine, particularly of the double cylinder type, with yarn finger for plated knitting, comprising at least one needle cylinder (2, 3) that has a plurality of axial grooves (4, 5) that each accommodate a needle (6); the needle cylinder (2, 3) is actuatable with a rotary motion about its own axis (2a), arranged vertically, with respect to at least one feed or drop at which there are at least two yarn fingers (7, 8) for plated knitting, respectively a first yarn finger (7) for dispensing a base yarn (9) and a second yarn finger (8) for dispensing a reinforcement yarn (10); the second yarn finger (8) has an elongated body that comprises a dispensing end (12), located proximate to a longitudinal end thereof and provided with a passage for the reinforcement yarn (10) to be

		dispensed to the needles (6) of the machine arranged in the needle cylinder (2, 3), and a remaining part (13) of the body of the second yarn finger (8); the second yarn finger (8) can be arranged so that its dispensing end (12) faces laterally the needle cylinder (2, 3) in the working area of the needles (6); the dispensing end (12) of the body of the second yarn finger (8) can move on command with respect to the remaining part (13) of the body of the second yarn finger (8), on a plane that is substantially perpendicular to the axis (2a) of the needle cylinder (2, 3), along a direction (14) that is substantially parallel to the tangent to the needle cylinder (2, 3) in the grip point, by the needles (6), of the reinforcement yarn (10) dispensed by the second yarn finger (8). 
236/2016	ELI LILLY AND COMPANY U.S.A.	"PHARMACEUTICALLY ACCEPTABLE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-2-CARBOXAMIDES" **142767** The present invention provides a pharmaceutically acceptable salt of a compound of Formula I:

		 Formula I Wherein R is H or F; and A is:  The present invention further provides a pharmaceutical composition comprising above said compound along with one or more pharmaceutically acceptable carriers, diluents, or excipients, which is useful in treating and preventing Alzheimer's disease.
466/2016	SANOFI-AVENTIS FRANCE.	"AN AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE" **142768** The present invention relates to an aqueous pharmaceutical formulation comprising 200- 500 U/mL [equimolar to 200- 500 IU human insulin] of insulin glargine and an analogue of exendin-4 selected from a group comprising lixisentatide, exenatide and liraglutide for use in the treatment of Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus.
305/2017	Novartis AG. Switzerland.	"PHARMACEUTICALLY ACCEPTABLE SALT OF ISOXAZOLE HYDROXAMIC ACID COMPOUND AS LpxC INHIBITOR" C07D413/06, C07D413/12 & A61K31/42. **142769** The present invention relates to a pharmaceutically

acceptable salt of a compound of Formula (I):



(I)

wherein:
X is —NH-, and R^1 is —CH(OH)-Y; or
X is —CH_2-, and R^1 is —CH(OH)-Y or —SO_2R^2
where R^2 is C_1-C_3 alkyl;
R^3 is H or halo;
Y is selected from a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S as ring members, phenyl, and C_{1-3} alkyl, and each Y is optionally substituted with one to three R^4;
each R^4 is independently selected from halo, C_{1-3} alkyl, and C_{3-6} cycloalkyl, wherein the C_{1-3} alkyl and C_{3-6} cycloalkyl are each optionally substituted with up to three groups selected from halo, CN and -OH;
L is —C=C- or —CR^5=CR^5-;
R5 is independently selected at each occurrence from H, halo and methyl; and
Z is selected from C_{1-6} alkyl, C_3-C_6 cycloalkyl, pyridinyl, and phenyl, each of which is optionally substituted with up to three groups selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} haloalkoxy, CN, and C_{1-4} alkyl that is optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C_{1-3} alkoxy;
or, when L is —CR^5=CR^5- , Z taken together with one of the R^5 groups and any atoms connecting Z with the R^5 group can form a 3-7 membered cycloalkyl or cycloalkenyl group that is optionally substituted with up to three groups selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} haloalkoxy, CN, and C_{1-4} alkyl that is optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C_{1-3} alkoxy.
The invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound of Formula (I) and

		a pharmaceutically acceptable carrier which therapeutically effective to treat bacterial infections caused by Gram-negative bacteria.
132/2018	EURO-CELTIQUE S.A., Luxembourg.	"Pharmaceutically Acceptable Salt of Dihydroetorphine" C07D489/12, A61K31/4353 & A61P20/100. **142770** The present invention provides a compound being a pharmaceutically acceptable salt or a derivative of a compound of formula (VI),  wherein R^1 and R^2 are independently C_{1-8} straight-chain alkyl and the * represents a (S) stereocentre.

SEALING FEES DUE-

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of **Rs.4500/-** should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
142647	Stamicarbon B.V. Netherlands.	349/2006
142648	Musarrat Akhter, SSO Dr. Nighar Sultana PSO PCSIR - Pakistan	807/2013
142649	Asahi Group Holdings, Ltd. Japan	357/2014
142650	POLICHEM SA Luxembourg.	104/2015

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
		09/04/2018	
1.	19246	Safety Guard Pair for Pillion Rider (project 7) with Adjustable Clamp (Class-01)	Hamza Afzaal S/o Afzaal Mustafa
2.	19247	Safety Guard Pair for Pillion Rider (project 7) with Adjustable Clamp (Class-03)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
3.	19248	Safety Guard Pair for Pillion Rider Project 8 with Adjustable Clamp (Class-01)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
4.	19249	Safety Guard Pair for Pillion Rider Project 8 with Adjustable Clamp (Class-03)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
5.	19250	Safety Guard Pair for Pillion Rider Project 8 Fixed Clamp (Class-03)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
6.	19251	Safety Guard Pair for Pillion Rider Project 8 Fixed Clamp (Class-01)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
7.	19252	Safety Guard Pair for Pillion Rider Project 7 Fixed Clamp (Class-03)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
8.	19253	Safety Guard Pair for Pillion Rider Project 7 Fixed Clamp (Class-01)	Afzaal Mustafa S/o Khan Ghulam Mustafa.
9.	19254	Mask (Class-03)	Reckitt Benckiser (Brands) Limited
10.	19255	Mask (Class-03)	Reckitt Benckiser (Brands) Limited
		10/04/2018	
11.	19256	Tin Box (Class-01)	Mr. Tahir Sultan Barry S/o Sultan Ahmed Barry trading as M/S S.Amden & Co.
12.	19257	Grip Pencill (Class-03)	Mr. Abdul Razzaq Saeed S/o Muhammad Saeed trading as M/S Marina Stationary Mart
13.	19258	Jar (Class-03)	Mr. Ozair Ur Rehman S/o Naim Ur Rehman Khan, trading as M/S. Samiya Cosmetics
14.	19259	Bottle (Class-03)	Mr. Ozair Ur Rehman S/o Naim Ur Rehman Khan, trading as M/S Noorani & Company
15.	19260	Flight Cut 14 panel Foot Ball (Class -06)	Sheikh Jahangir Iqbal

			(Chairman /CEO)
11/04/2018			
16.	19261	Packaging Box (Class-05)	Abrar Ahmed, M/s. National Cottage Industries
17.	19262	Packaging Box (Class-05)	Abrar Ahmed, M/s. National Cottage Industries
18.	19263	Jar and Plastic Bottle (class-03)	Rashid Nazir S/o Sheikh Muhammad Nazir Sole Proprietor; Pakistani National trading as Rashid Enterprises
19.	19264	Jar and Plastic Bottle (Class -03)	Rashid Nazir S/o Sheikh Muhammad Nazir Sole Proprietor; Pakistani National trading as Rashid Enterprises
20.	19265	Jar and Plastic Bottle (Class -03)	Rashid Nazir S/o Sheikh Muhammad Nazir Sole Proprietor; Pakistani National trading as Rashid Enterprises
21.	19266	Jar and Plastic Bottle (Class -03)	Rashid Nazir S/o Sheikh Muhammad Nazir Sole Proprietor; Pakistani National trading as Rashid Enterprises
22.	19267	Jar and Plastic Bottle (Class -03)	Rashid Nazir S/o Sheikh Muhammad Nazir Sole Proprietor; Pakistani National trading as Rashid Enterprises
23.	19268	Lid and Plastic Cap (Class -03)	Rashid Nazir S/o Sheikh Muhammad Nazir Sole Proprietor; Pakistani National trading as Rashid Enterprises
12/04/2018			
24.	19269	3 Wheel Passenger Vehicle (Class-01)	Sazgar Engineering Works Limited (a Pakistani company)
25.	19270	Spatula (Class-03)	Bayer Intellectual Property GmbH
13/04/2018			
26.	19271	Portable Geazer (Class-12)	M/s. Koh-i-Noor Hitech Pvt Ltd

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
		09/04/2018	
1.	18946	Sharpener (Class-03)	Sayyed Engineers Limited
2.	18945	Sharpener (Class-03)	Sayyed Engineers Limited
3.	18944	Sharpener (Class-03)	Sayyed Engineers Limited
4.	18943	Sharpener (Class-03)	Sayyed Engineers Limited
5.	18931	CEILING FAN (Class-01)	M/s. Parwaz Engineering Company (Private) Limited
6.	18932	CEILING FAN (Class-01)	M/s. Parwaz Engineering Company (Private) Limited
		10/04/2018	
7.	18335	Back Light (Class-03)	Sazgar Engineering Works Limited
8.	18413	Front Cowl (Class-03)	Sazgar Engineering Works Limited
		11/04/2018	
9.	18004	Almirah Pillar Design (Class-01)	M/s. Zam Zam Special Cooler & Safe Almirah
		12/04/2018	
10.	19095	Tray (Class-03)	DOVE MELAMINE WARE
11.	19028	Tooth Forceps & Pliers Handle (Class-01)	M/s Mid East Mfg
12.	19027	Bear Harp (Class-03)	M/s Mid East Mfg
13.	19026	Harp Lever (Class-01)	M/s Mid East Mfg
14.	19016	Samba Sharpener (Class-03)	Sayyed Engineers Limited
15.	19015	Piano Flo (Class-03)	Sayyed Engineers Limited

16.	19014	Glue Stick (Class-03)	Sayyed Engineers Limited
17.	19010	Piano Ink Cartridge (Class-03)	Sayyed Engineers Limited
18.	19009	Piano Classic Gel (Class-3)	Sayyed Engineers Limited
19.	18986	DRY FRUIT/CAKE RACK (Class-03)	EMSA PLASTIC INDUSTRIES
20.	18949	Induction Heating Coil for Leather Fleshing / Shaving Blade (Class-01)	Saheeb Ahmed Kayani
21.	18848	TYRE (LBR103) (Class-03)	M/S Shandong Linlong Tyre Co., Ltd
22.	18817	TYRE (COSSWIND R701*) (Class-03)	M/S Shandong Linlong Tyre Co., Ltd
23.	18800	Sports Ball (Class-12)	MOLTEN CORPORATION
24.	18761	INK BOTTLE (Class-03)	M/S Dollar Industries
25.	18664	Plastic Oil Bottle (Class-03)	Halal 19 Agrotech
26.	18397	Kajal Stick (Class-03)	Muhammad Hashim Tajir Surma
27.	18372	Plate (Class-03)	Dove Melamine ware
28.	18059	Plastic Shampoo Bottle (Class-03)	Marriana International
29.	17989	Air Cooler (Class-03)	M/s. Super Asia Muhammad Din Sons Limited
13/04/2018			
30.	18926	Gyro-Hit (Virtual Reality Defense Training System-VRDTS)" (Class-03)	Kamran Malik, Wasim Ahmad Khan, Danial Hussain Butt, Muhammad Furqan Khan
31.	17968	Adjustable Sport Paddle (Class-03l)	Mark Bonfigli
32.	17781	Bottle Cap (Class-03)	HSIL Limited
33.	19012	Piano Re-writer (Class-03)	Sayyed Engineers Limited

34.	19013	Piano Correction Pen (Class-03)	Sayyed Engineers Limited
35.	18899	Serving Dish with Lid (Class-03)	DOVE MELAMINE WARE
36.	18898	Plate (Class-03)	DOVE MELAMINE WARE
37.	18897	Bowl (Class-03)	DOVE MELAMINE WARE
38.	18766	Cap (Class-03)	M/s. svvitch
39.	18753	Bottle (Class-03)	M/s. svvitch
40.	18752	Bottle (Class-03)	M/s. svvitch
41.	18751	Cap (Class-03)	M/s. svvitch
42.	18750	Bottle (Class-03)	M/s. svvitch
43.	18672	Bottle (Class-03)	Al-Khair Crystoplast
44.	18633	Plastic Bottle (Class-03)	M/s. Pro Foods
45.	18615	A Hood (Class-03)	Sazgar Engineering Works Limited
46.	18118	Plastic Can (Class-03)	Pakistan Lubricants (Private) Limited
47.	17739	Holder For Back Mirror Of Vehicle (Class-03)	Hitech Industries
48.	17551	Small Seeded Drill (Class-01)	Muhammad Anwar S/O Noor Ahmad
49.	18580	INDUSTRIAL IMPACT SAFETY GLOVE (Class-03)	RINGERS TECHNOLOGIES, LLC

(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591